These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 2257872)

  • 21. Systolic time intervals in evaluation of the negative inotropic effect after single oral doses of mexiletine and disopyramide.
    Rousson D; Piolat C; Galleyrand J; Ferry S; Boissel JP
    Eur J Clin Pharmacol; 1986; 30(3):263-8. PubMed ID: 3732360
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of neglecting nonlinear plasma-protein binding on disopyramide bioavailability studies.
    Upton RA; Williams RL
    J Pharmacokinet Biopharm; 1986 Aug; 14(4):365-79. PubMed ID: 3772738
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disopyramide concentrations in human plasma and saliva: comparison of disopyramide concentrations in saliva and plasma unbound concentrations.
    Sagawa K; Mohri K; Shimada S; Shimizu M; Muramatsu J
    Eur J Clin Pharmacol; 1997; 52(1):65-9. PubMed ID: 9143870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative study of encainide and disopyramide in chronic ventricular arrhythmias: a double-blind placebo-controlled crossover study.
    Caron JF; Libersa CC; Kher AR; Kacet S; Wanszelbaum H; Dupuis BA; Poirier JM; Lekieffre JP
    J Am Coll Cardiol; 1985 Jun; 5(6):1457-63. PubMed ID: 2582017
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relative bioavailability of two disopyramide capsules in humans based on total, unbound, and unbound enantiomer concentrations.
    Takahashi H; Ogata H; Shimizu M; Hashimoto K; Masuhara K; Kashiwada K; Someya K
    Biopharm Drug Dispos; 1993 Jul; 14(5):409-18. PubMed ID: 8218959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disopyramide pharmacokinetics in the elderly after single oral administration.
    Roberto P; Vitaliano B; Donatella P; Raffaella M; Sergio B; Gabriella C
    Pharmacol Res Commun; 1988 Dec; 20(12):1025-34. PubMed ID: 3211990
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute effects of conventional oral dose of disopyramide on left atrial and ventricular functions.
    Arakawa M; Miwa H; Noda T; Kagawa K; Nishigaki K; Ito Y; Kawada T; Hirakawa S
    Int J Clin Pharmacol Ther Toxicol; 1993 May; 31(5):253-9. PubMed ID: 8314654
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of altered disopyramide binding on its pharmacologic response in rabbits.
    Huang JD; Oie S
    J Pharmacol Exp Ther; 1982 Nov; 223(2):469-71. PubMed ID: 7131300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the effects of clonidine and yohimbine on spontaneous pupillary fluctuations in healthy human volunteers.
    Phillips MA; Szabadi E; Bradshaw CM
    Psychopharmacology (Berl); 2000 May; 150(1):85-9. PubMed ID: 10867980
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacologic evaluation of standard and controlled-release disopyramide.
    Siddoway LA; Barbey JT; Roden DM; Woosley RL
    Angiology; 1987 Feb; 38(2 Pt 2):184-7. PubMed ID: 3103492
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the effects of binodaline and amitriptyline on peripheral autonomic functions in healthy volunteers.
    Longmore J; Szabadi E; Bradshaw CM
    Br J Clin Pharmacol; 1985 Mar; 19(3):295-300. PubMed ID: 3986084
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral disopyramide after admission to hospital with suspected acute myocardial infarction. U. K. Rythmodan Multicentre Study Group.
    Postgrad Med J; 1984 Feb; 60(700):98-107. PubMed ID: 6369290
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative bioavailability of disopyramide after multiple dosing with standard capsules and controlled-release tablets.
    Forssell G; Graffner C; Nordlander R; Nyquist O
    Eur J Clin Pharmacol; 1980; 17(3):209-13. PubMed ID: 7363933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bioavailability of disopyramide in normal volunteers using unbound concentration.
    Braun J; Sörgel F; Gluth WP; Oie S
    Eur J Clin Pharmacol; 1987; 32(6):625-9. PubMed ID: 3653232
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concentration-dependence of disopyramide binding to plasma protein and its influence on kinetics and dynamics.
    Lima JJ; Boudoulas H; Blanford M
    J Pharmacol Exp Ther; 1981 Dec; 219(3):741-7. PubMed ID: 7299695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In silico assessment of the effects of quinidine, disopyramide and E-4031 on short QT syndrome variant 1 in the human ventricles.
    Luo C; Wang K; Zhang H
    PLoS One; 2017; 12(6):e0179515. PubMed ID: 28632743
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic-dynamic study on different oral biperiden formulations in volunteers.
    Hollmann M; Müller-Peltzer H; Greger G; Brode E; Perucca E; Grimaldi R; Crema A
    Pharmacopsychiatry; 1987 Mar; 20(2):72-7. PubMed ID: 3588663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A double-blind, crossover comparison of flecainide acetate and disopyramide phosphate in the treatment of ventricular premature complexes.
    Kjekshus J; Bathen J; Orning OM; Storstein L
    Am J Cardiol; 1984 Feb; 53(5):72B-78B. PubMed ID: 6421140
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disopyramide plasma concentrations following single and multiple doses of the immediate- and controlled-release capsules.
    Karim A; Schubert EN; Burns TS; Palmer M; Zinny MA
    Angiology; 1983 Jun; 34(6):375-92. PubMed ID: 6346960
    [No Abstract]   [Full Text] [Related]  

  • 40. Oral disopyramide dosage regimes in ischaemic heart disease.
    Bryson SM; Fotheringham GH; Struthers MG; Whiting B
    J Clin Hosp Pharm; 1982 Mar; 7(1):37-42. PubMed ID: 7096577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.